ArticleHemaSphere2022

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy.

Lisa Argnani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.